Abstract | OBJECTIVE: BACKGROUND: Previous studies have suggested involvement of serotonergic systems in chronic tension-type headache (CTTH), but relevant experimental data are limited. Sumatriptan, a 5-HT1B/1D receptor agonist, stimulates the release of growth hormone (GH) and inhibits the release of ACTH, cortisol, and prolactin. These effects may be used to explore the function of serotonergic systems in vivo. METHODS: RESULTS: Placebo administration had no effect on hormone concentrations. GH and PRL secretion after sumatriptan administration was significantly (P<0.01 and <0.05) altered in CTTH patients in comparison with controls. CONCLUSION: Our results suggest that cerebral serotonergic functions mediated by 5-HT1D receptors are altered in CTTH.
|
Authors | I Rainero, W Valfrè, L Savi, M Ferrero, P Del Rizzo, P Limone, G C Isaia, L Gianotti, A Pollo, R Verde, F Benedetti, L Pinessi |
Journal | Headache
(Headache)
Vol. 42
Issue 8
Pg. 709-14
(Sep 2002)
ISSN: 0017-8748 [Print] United States |
PMID | 12390633
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Receptor, Serotonin, 5-HT1D
- Receptors, Serotonin
- Serotonin Receptor Agonists
- Sumatriptan
- Prolactin
- Growth Hormone
|
Topics |
- Adult
- Brain
(metabolism)
- Chronic Disease
- Female
- Growth Hormone
(blood, drug effects, metabolism)
- Humans
- Male
- Prolactin
(drug effects, metabolism)
- Receptor, Serotonin, 5-HT1D
- Receptors, Serotonin
(drug effects, metabolism)
- Serotonin Receptor Agonists
(metabolism, pharmacology)
- Sumatriptan
(metabolism, pharmacology)
- Tension-Type Headache
(metabolism)
|